Validating cancer drug targets (original) (raw)

• Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 1, 2640–2653 (2005).
  Article Google Scholar
• Emens, L. A. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am. J. Ther. 12, 243–253 (2005).
  PubMed Google Scholar
• Weinstein, I. Addiction to oncogenes: the Achilles Heel of Cancer. Science 297, 63–65 (2002).
  Article CAS PubMed Google Scholar
• Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).
  Article ADS CAS PubMed Google Scholar
• Kaelin, W. J. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689–698 (2005).
  Article CAS Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article ADS CAS PubMed Google Scholar
• Mills, G. P., Lu, Y. & Kohn, E. C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 10031–10033 (2001).
  Article ADS CAS PubMed PubMed Central Google Scholar
• O'Neill, J., Manion, M., Schwartz, P. & Hockenbery, D. M. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta 1705, 43–51 (2004).
  CAS PubMed Google Scholar
• Jensen, E. V. & Jordan, V. C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980–1989 (2003).
  CAS PubMed Google Scholar
• Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 26, 407–421 (1999).
  CAS PubMed Google Scholar
• Pitha-Rowe, I., Petty, W. J., Kitareewan, S. & Dmitrovsky, E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 17, 1723–1730 (2003).
  Article CAS PubMed Google Scholar
• Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
  Article ADS CAS PubMed Google Scholar
• Marx, J. Encouraging results for second generation anti-angiogenic drugs. Science 308, 1248–1249 (2005).
  Article CAS PubMed Google Scholar
• van Elsas, A. et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 149, 883–893 (1996).
  CAS PubMed PubMed Central Google Scholar
• Walker, F. & Olson, M. F. Targeting Ras and Rho GTPases as opportunities for cancer therapies. Curr. Opin. Genet. Dev. 15, 62–68 (2005).
  Article CAS PubMed Google Scholar
• Beeram, M., Patnaik, A. & Rowinsky, E. K. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol. 23, 6771–6790 (2005).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article ADS CAS PubMed Google Scholar
• Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19–20 (2003).
  Article CAS PubMed Google Scholar
• Thompson, N. & Lyons, J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 5, 350–356 (2005).
  Article CAS PubMed Google Scholar
• Janne, P. A., Engelman, J. A. & Johnson, B. E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227–3234 (2005).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–500 (2004).
  Article ADS CAS PubMed Google Scholar
• Rao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
  Article ADS Google Scholar
• Tsao, M. S. et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–134 (2005).
  Article CAS PubMed Google Scholar
• Patel, J. D., Pasche, B. & Argiris, A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit. Rev. Oncol. Hematol. 50, 175–186 (2004).
  Article PubMed Google Scholar
• Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 102, 3788–3793 (2005).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Shih, C. & Weinberg, R. A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161–169 (1982).
  Article CAS PubMed Google Scholar
• Silva, J., Chang, K., Hannon, G. J. & Rivas, F. V. RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene 23, 8401–8409 (2004).
  Article CAS PubMed Google Scholar
• Torrance, C. J., Agrawal, V., Vogelstein, B. & Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnol. 19, 940–945 (2001).
  Article CAS Google Scholar
• Kohli, M., Rago, C., Lengauer, C., Kinzler, K. W. & Vogelstein, B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res. 32, e3 (2004).
  Article PubMed PubMed Central Google Scholar
• Mazurier, F., Doedens, M., Gan, O. I. & Dick, J. E. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD–SCID mice reveals a new class of human stem cells. Nature Med. 9, 959–963 (2003).
  Article CAS PubMed Google Scholar
• Brumby, A. M. & Richardson, H. E. Using Drosophila melanogaster to map human cancer pathways. Nature Rev. Cancer 5, 626–639 (2005).
  Article CAS Google Scholar
• Amatruda, J. D., Shepard, J. L., Stern, H. M. & Zon, L. I. Zebrafish as a cancer model system. Cancer Cell 1, 229–231 (2002).
  Article CAS PubMed Google Scholar
• Simon, J. A. Yeast as a model system for anticancer drug discovery. Expert Opin. Ther. Targets 5, 177–195 (2001).
  CAS PubMed Google Scholar
• Hengartner, M. O. & Horvitz, H. R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76, 665–676 (1994).
  Article CAS PubMed Google Scholar
• Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161–165 (2005).
  Article CAS Google Scholar
• Sausville, E. A. Target selection issues in drug discovery and development. J. Chemother. Suppl. 16 (suppl. 4), 16–18 (2004).
  Article CAS Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
  Article CAS PubMed Google Scholar
• Bachman, K. E. et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772–775 (2004).
  Article CAS PubMed Google Scholar
• Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005).
  Article CAS PubMed Google Scholar
• Aoki, M., Jiang, H. & Vogt, P. K. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc. Natl Acad. Sci. USA 101, 13613–13617 (2004).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Lengauer, C., Diaz, L. A. & Saha, S. Cancer drug discovery through collaboration. Nature Rev. Drug Discov. 4, 375–380 (2005).
  Article CAS Google Scholar
• Salloukh, H. F., Vowles, I., Heisterkamp, N., Groffen, J. & Laneuville, P. Early events in leukemogenesis in P190Bcr–abl transgenic mice. Oncogene 19, 4362–4374 (2000).
  Article CAS PubMed Google Scholar
• Lefevre, G. et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J. Biol. Chem. 279, 31769–31779 (2004).
  Article CAS PubMed Google Scholar
• Mitsiades, C. S., Mitsiades, N. & Koutsilieris, M. The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4, 235–256 (2004).
  Article CAS PubMed Google Scholar
• Kitayama, H. et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88, 995–1004 (1996).
  CAS PubMed Google Scholar
• Cool, M., Depault, F. & Jolicoeur, P. Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci. Genes Chromosomes Cancer 45, 191–202 (2006).
  Article CAS PubMed Google Scholar
• Kang, C. S. et al. An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J. Neurooncol. 73, 267–273 (2005).
  Article Google Scholar
• Kim, H. & Muller, W. J. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253, 78–87 (1999).
  Article CAS PubMed Google Scholar
• Early, E. et al. Transgenic expression of PML/RARα impairs myelopoiesis. Proc. Natl Acad. Sci. USA 93, 7900–7904 (1996).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Park, D. J., Vuong, P. T., de Vos, S., Douer, D. & Koeffler, H. P. Comparative analysis of genes regulated by PML/RARα and PLZF/RARα in response to retinoic acid using oligonucleotide arrays. Blood 102, 3727–3736 (2003).
  Article CAS PubMed Google Scholar
• Lewis, J. S. et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl Cancer Inst. 97, 1746–1759 (2005).
  Article CAS PubMed Google Scholar
• Lu, M., Mira- y-Lopez, R., Nakajo, S., Nakaya, K. & Jing, Y. Expression of estrogen receptor α, retinoic acid receptor α and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. Oncogene 24, 4362–4269 (2005).
  Article CAS PubMed Google Scholar
• Yue, W. et al. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin. Cancer Res. 11, 9225s–9230s (2005).
  Google Scholar
• Nair, H. B. et al. Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res. 65, 11164–11173 (2005).
  Article CAS PubMed Google Scholar
• Ratliff, T. L. Mutation of the androgen receptor causes oncogenic transformation of the prostate. J. Urol. 174, 1149 (2005).
  PubMed Google Scholar
• Tao, J. et al. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 153, 715–724 (2005).
  Article CAS PubMed Google Scholar